Clinical Oncology Next Generation Sequencing Market Value is Expected to Reach $660.87 Million by 2023 | COVID 19 Growth And Change | TBRC Reports

The Business Research Company offers "Clinical Oncology Next Generation Sequencing Global Market Report 2020-30: COVID 19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.

The global clinical oncology next generation sequencing market is expected to decline from $447.28 billion in 2019 to $437.55 billion in 2020 at a compound annual growth rate (CAGR) of -2.18%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $660.87 million in 2023 at a CAGR of 14.74%.

Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

The clinical oncology next generation sequencing market consists of sales of devices and equipment used in clinical oncology next generation sequencing and related services by entities (organizations, sole traders and partnerships) that manufacture clinical oncology next generation sequencing equipment. Next generation sequencing is a process used to determine the sequence of nucleotides in a section of DNA and is used for oncology research. Only goods and services traded between entities or sold to end consumers are included.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for clinical oncology next generation sequencing market.

Clinical Oncology Next Generation Sequencing Market Segmentation: -
By Technology
Ion Semiconductor Sequencing
Pyro-Sequencing
Synthesis Sequencing
Real Time Sequencing
Ligation Sequencing
Reversible Dye Termination Sequencing
Nano-Pore Sequencing

By Application
Screening
Companion Diagnostics
Other Diagnostics

By End User
Hospital Laboratories
Clinical Research Oraganizations
Diagnostic laboratories

Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report-2020-30-covid-19-growth-and-change

Few Points From Table Of Content
1. Executive Summary
2. Clinical Oncology Next Generation Sequencing Market Characteristics
3. Clinical Oncology Next Generation Sequencing Market Size And Growth
4. Clinical Oncology Next Generation Sequencing Market Segmentation
5. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis
.
.
25. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles
26. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market
27. Clinical Oncology Next Generation Sequencing Market Trends And Strategies
28. Clinical Oncology Next Generation Sequencing Market Future Outlook and Potential Analysis
29. Appendix

The report covers the trends and market dynamics of the Clinical Oncology Next Generation Sequencing Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample Copy of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Some of the key players involved in the Clinical Oncology Next Generation Sequencing Market are Thermo Fisher Scientific(Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche.

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.